Financial News Feed

Weaker Buy Today RETA ranks #1018 as BUY CANDIDATE. Stronger Buy
Today RETA ranks #1018 as BUY CANDIDATE.

RETA stock RETA

RETA stock
RETA

Investors might be trying to gauge which way shares of Reata Pharmaceuticals, Inc. (:RETA) will swing over the next couple of quarters. In recent trading activity, the stock has been seen near the $71... Read more
The world’s second-largest cinema chain, Cineworld Group PLC (LON:CINE), welcomed a record 308mln customers into its theatres in 2018. The standout performer was the US business, with Cineworld reap... Read more
The ERP5 Rank is an investment tool that analysts use to discover undervalued companies. The ERP5 looks at the Price to Book ratio, Earnings Yield, ROIC and 5 year average ROIC. The ERP5 of Reata Phar... Read more
Reata Pharmaceuticals, Inc. (NasdaqGM:RETA) has an ERP5 rank of 16279. The ERP5 Rank is an investment tool that analysts use to discover undervalued companies. The ERP5 looks at the Price to Book rati... Read more
As earnings reports continue to roll in, investors may be taking a closer look at companies that they own. Staying on top of the most recent releases may help investors figure out if the company is we... Read more
Here we will take a look at the Gross Margin Score of Reata Pharmaceuticals, Inc. (NasdaqGM:RETA) shares. The equity currently has a score of 50.00000. This score is derived from the Gross Margin (Mar... Read more
Scanning the equity markets, it is quite obvious that there are plenty of stocks to choose from. This may make things a bit overwhelming for the beginner investor, but it should also be seen as a grea... Read more
Reata Pharmaceuticals Inc (NASDAQ:RETA) CFO Jason Douglas Wilson sold 20,000 shares of the firm’s stock in a transaction dated Monday, January 7th. The stock was sold at an average price of $72.04, ... Read more
Reata Pharmaceuticals Inc (NASDAQ:RETA) CFO Jason Douglas Wilson sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, January 7th. The stock was sold at an average pr... Read more
Smart investors are constantly on the lookout for a bargain when it comes to stock picking. As of late, investors have been taking a second look at shares of Reata Pharmaceuticals, Inc. (:RETA). Durin... Read more
Investors may be tracking sell-side analyst opinions on shares of Reata Pharmaceuticals, Inc. (:RETA). According to analysts polled by Zacks Research, the current consensus target price is $131.57. An... Read more
IRVING, Texas, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (NASDAQ: RETA ), a clinical-stage biopharmaceutical company, today announced the appointment of Geoffrey A. Block, M.D., as... Read more
The stock of Reata Pharmaceuticals, Inc. (RETA) formed H&S with $56.08 target or 5.00 % below today's $59.03 share price. The 5 months Head & Shoulders... Read more
The Piotroski F-Score is a scoring system between 1-9 that determines a firm’s financial strength. The score helps determine if a company’s stock is valuable or not. The Piotroski F-Score of Reata... Read more
The EBITDA Yield for William Hill plc (LSE:WMH) is -0.273219. The EBITDA Yield is a great way to determine a company’s profitability. This number is calculated by dividing a company’s earnings bef... Read more

News Feed powered by

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank